Simulect

Simulect is a drug prescribed to help prevent the body from rejecting a newly transplanted kidney. It must be used in combination with other anti-rejection medicines. Side effects may include constipation, nausea, and headaches. This medication comes as a powder that is dissolved in fluid and given as an intravenous (IV) injection.

What Is Simulect?

Simulect® (basiliximab) is a prescription medication approved to prevent the body from rejecting a newly transplanted kidney. It is used in combination with other anti-rejection medications, including cyclosporine (Gengraf®, Neoral®, Sandimmune®) and a corticosteroid.
 
(Click Simulect Uses for more information on this topic, including possible off-label uses.)
 

Who Makes This Medication?

Simulect is manufactured by Novartis Pharmaceuticals Corporation.
 

How Does Simulect Work?

Transplant rejection occurs when the immune system recognizes a transplanted organ as foreign and attacks it. T lymphocytes (a white blood cell type, sometimes simply called T cells) are an important part of the immune response involved in transplant rejection.
 
An antibody is a protein made by the immune system. Antibodies attach to substances in the body called antigens. Simulect is a manufactured antibody designed to bind to a specific antigen (known as CD25) found on the surface of T cells. Normally, interleukin-2 (a protein made by the body) binds to CD25 and stimulates T cells to mature and divide.
 
By binding to CD25, Simulect blocks the action of interleukin-2, thus preventing T cells from multiplying. This decreases the number of T cells in the body and reduces the risk for transplant rejection.
 

Simulect Medication Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.